Decreases in H2Bub1 and RNF20/40 levels observed in certain advanced cancers, such as colorectal and breast cancers [60], suggest H2Bub1 and H2B ubiquitylation enzymes as cancer markers and novel targets for cancer therapy. Here, RNF20 is linked to breast carcinoma.